These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38352845)

  • 1. 3-Alkynyl Carboxamides as AEP Modulators for Treating Alzheimer's Disease.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2024 Feb; 15(2):159-160. PubMed ID: 38352845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Haloacethydrazides as AEP Inhibitors for Treating Alzheimer's Disease.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2023 Sep; 14(9):1165-1166. PubMed ID: 37736172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2024 Jun; 15(6):750-751. PubMed ID: 38894913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxylic Acid-Containing Indanyl Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2023 Aug; 14(8):1033-1034. PubMed ID: 37583826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):899-900. PubMed ID: 37465291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1047-1048. PubMed ID: 37583813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.
    Sabnis RW
    ACS Med Chem Lett; 2024 Apr; 15(4):447-448. PubMed ID: 38628797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Substituted Cyclopropyl Compounds as CFTR Modulators for Treating Cystic Fibrosis.
    Sabnis RW
    ACS Med Chem Lett; 2022 Oct; 13(10):1552-1553. PubMed ID: 36262401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asparagine endopeptidase-targeted Ultrasound-responsive Nanobubbles Alleviate Tau Cleavage and Amyloid-β Deposition in an Alzheimer's Disease Model.
    Mi X; Du H; Guo X; Wu Y; Shen L; Luo Y; Wang D; Su Q; Xiang R; Yue S; Wu S; Gong J; Yang Z; Zhang Y; Tan X
    Acta Biomater; 2022 Mar; 141():388-397. PubMed ID: 35045359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.
    Sabnis RW
    ACS Med Chem Lett; 2023 May; 14(5):553-554. PubMed ID: 37197462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 2,5-Diazabicyclo[4.2.0]octanes as GLP-1 Receptor Modulators for Treating Type 2 Diabetes.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jun; 14(6):709-710. PubMed ID: 37312848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoacylglycerol Lipase Modulators for Treating Autism Spectrum Disorders.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2023 May; 14(5):545-546. PubMed ID: 37197472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Brain evoked potentials in patients with Alzheimer's disease and schizophrenia: a comparative study].
    Chen X; Zhang M; Wang J
    Zhonghua Yi Xue Za Zhi; 1998 Sep; 78(9):674-6. PubMed ID: 11038791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer's disease via modulating neuropathology and gut microbiota through suppressing C/EBPβ/AEP pathway.
    Xu QQ; Su ZR; Yang W; Zhong M; Xian YF; Lin ZX
    J Neuroinflammation; 2023 Jan; 20(1):19. PubMed ID: 36717922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of the Asparaginyl Endopeptidase (AEP) in an Alzheimer's Disease Model Improves the Survival and Efficacy of Transplanted Neural Stem Cells.
    Cheng Q; Ma X; Liu J; Feng X; Liu Y; Wang Y; Ni W; Song M
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer's disease-related pathologies in a senescence-accelerated mouse model.
    Wang J; Hu HJ; Liu ZK; Liu JJ; Wang SS; Cheng Q; Chen HZ; Song M
    Transl Neurodegener; 2021 Mar; 10(1):12. PubMed ID: 33789744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases.
    Zhang Z; Xie M; Ye K
    Expert Opin Ther Targets; 2016 Oct; 20(10):1237-45. PubMed ID: 27115710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Heterocyclic Compounds for Treating Huntington's Disease.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2024 Mar; 15(3):324-325. PubMed ID: 38505841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C/EBPβ/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer's disease.
    Liao J; Chen G; Liu X; Wei ZZ; Yu SP; Chen Q; Ye K
    Mol Psychiatry; 2022 Jul; 27(7):3034-3046. PubMed ID: 35422468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traumatic brain injury triggers APP and Tau cleavage by delta-secretase, mediating Alzheimer's disease pathology.
    Wu Z; Wang ZH; Liu X; Zhang Z; Gu X; Yu SP; Keene CD; Cheng L; Ye K
    Prog Neurobiol; 2020 Feb; 185():101730. PubMed ID: 31778772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.